乙肝病人血浆中触珠蛋白和补体B因子的检测及临床意义  

The decrease of haptoglobin and complement factor B with the disease progression in patients with viral hepatitis B

作　　者：王冯滨[1] 杨海英[1] 欧强[1] 

机构地区：[1]上海市（复旦大学附属）公其卫生临床中心感染科,上海201508

出　　处：《公共卫生与临床医学》2009年第3期192-193,210,共3页Public health and dinical medicine

基　　金：上海市卫生局青年课题（2007041）,中国肝炎防治基金会课题（200704）

摘　　要：目的探讨触珠蛋白（HP）和补体B因子（CFB）在乙型肝炎（以下简称乙肝）中的变化规律及其临床意义。方法采用ELISA检测乙肝病人和正常健康者血浆HP和CFB表达水平。同时检测凝血酶原活动度（PTA）。结果慢性乙型肝炎（以下简称慢乙肝）和慢性重型乙型肝炎组（以下简称慢重乙肝组）血浆HP和CFB表达水平明显降低，与正常对照组比较有非常显著性差异（P〈0．01）；慢乙肝和慢重乙肝组两组之间血浆HP和CFB表达水平比较亦有非常显著性差异（P〈0．01）。与存活组相比，死亡组的PTA值、血浆HP和CFB水平明显降低，差异有显著性（P〈0．05或P〈0．01）。结论乙肝病人血浆HP和CFB表达水平明显下降。血浆HP和CFB水平的检测对评估乙肝病人肝功能损害的严重程度和判断预后具有重要的参考价值。Objective To quantify the haptoglobin （liP） and complement factor B （CFB） in patients with viral hepatitis B infection at different clinical stages. Methods Plasma HP and CFB were quantified by Enzyme-linked Immunosorbent Assay （ELISA） in 85 patients with viral hepatitis B. Plasma PTA were also determined. Results The levels of Plasma HP and CFB in chronic hepatitis and severe chronic hepatitis groups were significantly lower than that in healthy donor group （P〈0.01）. Significant differences on plasma HP and CFB were also observed between chronic hepatitis and severe chronic hepatitis groups （P〈0.01）. The level of plasma HP, CFB and PTA in the group with death outcome were dramatically lower than that of alive group （P〈0.05 or P〈0.01）, Conclusions The levels of plasma HP and CFB decreased in patients with viral hepatitis B during the disease progression and have important implications to evaluate the damage of liver functionality and to judge the prognosis.

关 键 词：乙型肝炎 触珠蛋白 补体B因子 预后 

分 类 号：R512.62[医药卫生—内科学]